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Summary
Objective: To test the importance of the interleukin-4 (IL-4)/IL-4 receptor (IL-4R) system in osteoarthritis (OA) we evaluated soluble IL-4R
(sIL-4R) levels in sera of patients with different forms of OA and healthy individuals.
Methods: We recruited: 141 patients with hand OA, 70 with nodal and 71 with erosive hand OA; 64 patients undergoing total joint replacement,
34 with hip and 30 with knee OA; and 38 ethnically and geographically age-matched healthy individuals [normal controls (NC)].
Results: Serum sIL-4R concentration was found to be signiﬁcantly higher in all OA patients than that in NC. When patients were divided into
four subgroups (nodal, erosive, hip and knee OA) signiﬁcant differences were present when comparing NC with each subgroup. This was true
also when small-joint OA groups were compared with large-joint OA groups, the latter being associated with higher IL-4R levels.
Conclusions: We found increased levels of sIL-4R in OA patients compared with healthy individuals. We speculate that this reduces availabil-
ity of IL-4, and its effects on chondrocytes.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a degenerative joint disease charac-
terised by a loss of balance between the anabolic and cat-
abolic functions of chondrocytes. Enhanced breakdown of
cartilage matrix and reduced synthesis of matrix compo-
nents by articular chondrocytes eventually lead to the de-
struction of the affected tissue1. Cytokines and growth
factors seem to be involved in regulating cartilage degrada-
tion as well as synthesis2. Interleukin-1 beta (IL-1b) and
tumour necrosis factor alpha (TNF-a) have been shown
to inhibit chondrocyte proteoglycan synthesis, while
interleukin-4 (IL-4), interleukin-10 (IL-10) and interleukin-
13 (IL-13) have been shown to prevent and reverse
cartilage degradation in vitro3.
IL-4 exhibits potent anti-inﬂammatory activities by inhibit-
ing synthesis of IL-1b and TNF-a and by down regulating
many effects of these cytokines4. IL-4 induces its cellular re-
sponses by binding to a multimeric receptor. The primary
subunit of the IL-4 receptor (IL-4R), the a subunit, can com-
bine with the common gamma chain of the interleukin-2 re-
ceptor or the a0 subunit of the IL-13 receptor. Thus, different
IL-4Rs can be found in different cells. Human IL-4Ra exists
either as a membrane-bound receptor (IL-4R), or as soluble
one [soluble IL-4R (sIL-4R)]5. The latter is produced by pro-
teolytic shedding of the membrane-bound form6, or by
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Received 11 March 2005; revision accepted 28 February 2006.alternative splicing of the gene5. Depending on its molar ra-
tio to IL-4, sIL-4R can augment or neutralise IL-4 in vitro7.
To assess whether the IL-4/IL-4R system was involved in
OA, we measured soluble IL-4R levels in sera of patients
with different forms of OA.
Methods
Measurements were made in four groups of patients with
OA and a control group. The ﬁrst two groups were recruited
among consecutive men and women who attended six
rheumatological units in Italy, with a special interest in
OA. Patients with hand OA were diagnosed following clini-
cal and radiological evaluations8. Subjects had evidence
of hard tissue enlargement and/or deformity in three or
more index hand joints. Hand radiographs were used to
subdivide hand OA patients into nodal and erosive groups.
Erosive OA was deﬁned by central erosions (‘‘gull-wing’’
erosions) and/or ankylosis in the interphalangeal joints in
at least three digits, associated with joint-space narrowing,
subchondral sclerosis and/or osteophytes. We recruited
141 patients (eight male, 133 female; mean age 62.4 years
(yrs), SD 9.2, range 44e85 yrs), 70 with nodal (three
male, 67 female; mean age 59 yrs, SD 9.6, range
44e85 yrs) and 71 with erosive (ﬁve male, 66 female;
mean age 64.4 yrs, SD 8.3, range 44e82 yrs) hand OA.
Less than 30% of the patients were presented with manifes-
tations of OA at the spine, hip or knee. Patients with a his-
tory of other rheumatic or skeletal diseases were excluded
from analysis. In particular, for patients with erosive OA,717
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excluded.
The third and fourth groups were recruited from consecu-
tive men and women admitted to the Istituti Ortopedici
Rizzoli in Bologna (Italy) for total joint replacement. These
patients were diagnosed, following clinical and radiological
evaluations, as having either idiopathic hip or knee OA with-
out known metabolic, traumatic, congenital or endocrine
causes9,10, with a KellgreneLawrence radiological score
of 3e4. We recruited 64 patients (21 male, 43 female;
mean age 69.5 yrs, SD 8.4, range 39e86 yrs), 34 with
hip OA (15 male, 19 female; mean age 67.6 yrs,
SD 9.8, range 39e86 yrs) and 30 with knee OA (six
male, 24 female; mean age 71.6 yrs, SD 5.8, range
57e81 yrs). Patients with a history of other rheumatic or
skeletal diseases were excluded from analysis. Patients
were classiﬁed radiographically as described by Altman
et al.11. For each patient clinical, radiological and laboratory
data were collected, and coded for conﬁdentiality. We also
analysed 38 ethnically and geographically age-matched
healthy individuals (eight male, 30 female; mean age 66.7
yrs, SD 9.5, range 37e79 yrs), fulﬁlling the admission cri-
teria of the SENIEUR protocol12. Clinical evidence of OA at
the hand, knee or hip was excluded. Informed consent was
obtained from each patient. The study was approved by the
ethics committees of the hospitals involved. For each indi-
vidual enrolled in the study, venous blood was drawn for
serum and plasma separation. Soon after collection, vacu-
tainers were centrifuged at 2000 rpm for 10 min in order to
obtain serum and plasma, which were stored at 80(C
for further analysis. sIL-4R serum concentrations were mea-
sured by immunoassay using a commercial enzyme-linked
immunosorbent assay (ELISA) kit (R&D Systems, Minnea-
polis, MN), according to the manufacturer’s instructions.
The detection limit was 5 pg/mL.
STATISTICAL ANALYSES
Continuous variables were subjected to a KruskaleWallis
test and a ManneWhitney U test for unpaired data. Regres-
sion analyses and Spearman R correlation tests were also
performed.
Results and discussion
Serum sIL-4R concentrations in all OA patients were
increased in comparison with normal controls (NC)
(NC¼ 25.6 pg/mL (median), total OA¼ 35.7 pg/mL (me-
dian), P< 0.001). When patients were divided into four
groups (nodal, erosive, hip and knee OA) signiﬁcant differ-
ences (P< 0.001) from controls were present for each com-
parison, but there were no differences between nodal and
erosive OA, and hip vs knee OA (Fig. 1). This was true
also when small-joint OA groups were compared with
large-joint OA groups, the latter being associated with
higher sIL-4R levels. Regression analysis and correlations
showed no signiﬁcant association between either sex or
age and sIL-4R serum levels in all groups.
In this study, we measured the concentration of sIL-4R in
the sera of patients with primary OA at the hand, hip or
knee. We showed that sIL-4R levels were signiﬁcantly in-
creased in sera from patients compared with controls.
Levels of sIL-4R were increased in comparison with con-
trols in the whole group of OA patients as well as in the
subgroups with hand, hip and knee OA. IL-4 is expressed
in normal articular cartilage and has chondroprotectiveeffects in vitro, inhibiting IL-1-induced production of metallopro-
teinases by chondrocytes13. IL-4 is also involved in mechano-
transduction in normal human articular chondrocytes14, via
an autocrine/paracrine loop. IL-4 is produced by the cell in
response to mechanical stimulation, binds to receptors on
chondrocytes, and drives a signalling cascade leading to
activation of ion channels and aggrecan synthesis. Optimal
mechanical stimulation maintains articular cartilage struc-
ture and function, whereas abnormal mechanical forces
lead to loss of cartilage and the onset of OA. Chondrocytes
from OA cartilage do not show the same response to me-
chanical stimulation as normal cells14. Whatever the mech-
anism involved, in OA, the anabolic and protective effect of
IL-4 seems to fail. This could be caused by an alteration of
the IL-4/IL-4R system at any level: reduction of IL-4 action/
availability, receptor down-regulation, or signalling impair-
ment. It has been shown that low concentrations of sIL-
4R, compared with those of IL-4, enhance IL-4 activity,
while higher concentrations have the opposite effect7.
This may be involved in the control of IL-4 activity in normal
conditions. sIL-4R produced by alternative splicing5 is prob-
ably regulated by IL-4 via STAT, as it is in mice15, while
production following proteolysis is under the control of
metalloproteases6. In OA, over-production of such enzymes
has been demonstrated1. Thus increased production of sIL-
4R in OA might be the consequence of enhanced proteoly-
sis of the membrane form. In a recent paper by Forster
et al.16, two single nucleotide polymorphisms (SNPs) in
the IL-4R gene have been associated with susceptibility to
hip OA in a group of patients undergoing total joint replace-
ment. Both SNPs are located in the intracellular portion
of IL-4R and can affect the binding and phosphorylation of
the intracellular substrates STAT6 and IRS. This indirect
evidence of IL-4R involvement in OA probably exerts its ef-
fects through changes in the signalling cascade. The in-
creased production of sIL-4R observed in patients could
result in reduced availability of IL-47 and a reduction in
the effects of IL-4 on chondrocytes. To substantiate such
a hypothesis it would be necessary to measure IL-4 and
IL-4R levels simultaneously in the same patients.
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Fig. 1. Serum levels of sIL-4R in patients with nodal OA, erosive
OA, hip OA, knee OA and in healthy individuals (NC). Squares
show median, boxes 25th and 75th percentiles, and whiskers
10th and 90th percentiles. Signiﬁcant difference (P< 0.001) was
present for each comparison, except for nodal vs erosive OA,
and hip vs knee OA.
719Osteoarthritis and Cartilage Vol. 14, No. 7Furthermore, systemic sIL-4R levels may be inﬂuenced by
local levels in cartilage and synovial ﬂuid. We have demon-
strated that involvement of large joints such as the hip and
knee was associated with signiﬁcantly higher concentra-
tions of sIL-4R, when compared with levels in patients
with hand OA. One can speculate that this could be due
to differences in joint size, or disease state. In order to as-
certain whether serum measurements of sIL-4R will be
a useful tool for disease monitoring, longitudinal studies of
patients with early as well as late OA should be performed
to assess the value of sIL-4R as disease marker.
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